Melatonin in bone health

Melatonin in the Promotion of Health: Second Edition

Volumn , Issue , 2011, Pages 261-270

  Witt Enderby, Paula A ^a   Clafshenkel, William P ^a   Kotlarczyk, Mary P ^a   Sethi, Shalini ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859700115     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (69)

1. Burge, R, Dawson-Hughes, B, Solomon, DH, Wong, JB, King, A, Tosteson, A. 2007. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22: 465-475
2. Nochowitz, B, Siegert, S, Wasik, M. 2009. An update on osteoporosis. Am J Ther 16: 437-445
3. Kalu, DU. 1995. Evolution of the pathogenesis of postmenopausal bone loss. Bone 17: 135S-144S
4. Feskanich, D, Hankinson, SE, Schernhammer, ES. 2009. Nightshift work and fracture risk: The Nurses' Health Study. Osteoporos Int 20: 537-542
5. Grant, SG, Melan, MA, Latimer, JJ, Witt-Enderby, PA. 2009. Melatonin and breast cancer: Cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med 11: e5
6. Sanchez-Barcelo, EJ, Mediavilla, M.D., Reiter, R.J. 2010. Scientific basis for the potential use of melatonin in bone diseases: Osteoporosis and adolescent idiopathic scoliosis. J Osteoporosis. doi: 10.4061/2010/830231
7. Yarom, N, Yahalom, R, Shoshani, Y, Hamed, W, Regev, E, Elad, S. 2007. Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18: 1363-1370
8. Abrahamsen, B, Eiken, P, Eastell, R. 2009. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study. J Bone Miner Res 24: 1095-1102
9. Bilezikian, JP. 2008. Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window. Curr Osteoporos Rep 6: 24-30
10. Yasothan, U, Kar, S. 2008. Osteoporosis: Overview and pipeline. Nat Rev Drug Discov 7: 725-726
11. Shifren, JL, Schiff, I. 2010. Role of hormone therapy in the management of menopause. Obstet Gynecol 115: 839-855
12. Gennari, L, Merlotti, D, Nuti, R. 2010. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: Focus on lasofoxifene. Clin Interv Aging 5: 19-29
13. Cardinali, DP, Ladizesky, MG, Boggio, V, Cutrera, RA, Mautalen, C. 2003. Melatonin effects on bone: Experimental facts and clinical perspectives. J Pineal Res 34: 81-87
14. Witt-Enderby, PA, Radio, NM, Doctor, JS, Davis, VL. 2006. Therapeutic treatments potentially mediated by melatonin receptors: Potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res 41: 297-305
15. Sack, RL, Lewy, AJ, Erb, DL, Vollmer, WM, Singer, CM. 1986. Human melatonin production decreases with age. J Pineal Res 3: 379-388
16. Waldhauser, F, Weiszenbacher, G, Frisch, H, Zeitlhuber, U, Waldhauser, M, Wurtman, RJ. 1984. Fall in nocturnal serum melatonin during prepuberty and pubescence. Lancet 1: 362-365
17. Ladizesky, MG, Cutrera, RA, Boggio, V et al. 2001. Effect of melatonin on bone metabolism in ovariectomized rats. Life Sci 70: 557-565
18. Uslu, S, Uysal, A, Oktem, G, Yurtseven, M, Tanyalcin, T, Basdemir, G. 2007. Constructive effect of exogenous melatonin against osteoporosis after ovariectomy in rats. Anal Quant Cytol Histol 29: 317-325
19. Brodner, W, Krepler, P, Nicolakis, M et al. 2000. Melatonin and adolescent idiopathic scoliosis. J Bone Joint Surg Br 82: 399-403
20. Moreau, A, Wang DA, S, Forget, S et al. 2004. Melatonin signaling dysfunction in adolescent idiopathic scoliosis. Spine 29: 1772-1781
21. Azeddine, B, Letellier, K, Wang DA, S, Moldovan, F, Moreau, A. 2007. Molecular determinants of melatonin signaling dysfunction in adolescent idiopathic scoliosis. Clin Orthop Relat Res 462: 45-52
22. Zawilska, JB, Skene, DJ, Arendt, J. 2009. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep 61: 383-410
23. Greenspan, SL, Dresner-Pollak, R, Parker, RA, London, D, Ferguson, L. 1997. Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int 60: 419-423
24. Heshmati, HM, Riggs, BL, Burritt, MF, Mcalister, CA, Wollan, PC, Khosla, S. 1998. Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women. J Clin Endocrinol Metab 83: 751-756
25. Hassager, C, Risteli, J, Risteli, L, Jensen, SB, Christiansen, C. 1992. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res 7: 1307-1311
26. Ostrowska, Z, Kos-Kudla, B, Marek, B, Kajdaniuk, D. 2003. Influence of lighting conditions on daily rhythm of bone metabolism in rats and possible involvement of melatonin and other hormones in this process. Endocr Regul 37: 163-174
27. Ostrowska, Z, Kos-Kudla, B, Marek, B, Swietochowska, E, Gorski, J. 2001. Assessment of the relationship between circadian variations of salivary melatonin levels and type I collagen metabolism in postmenopausal obese women. Neuro Endocrinol Lett 22: 121-127
28. Graham, C, Cook, MR, Gerkovich, MM, Sastre, A. 2001. Examination of the melatonin hypothesis in women exposed at night to EMF, or bright light. Environ Health Perspect 109: 501-507
29. Torres, J, Tamimi, F, Garcia, I, Cebrian, JL, Lopez-Cabarcos, E, Lopez, A. 2008. Management of atrophic maxilla in severe osteoporosis treated with bisphosphonates: A case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106: 668-672
30. Ruggiero, SL, Mehrotra, B, Rosenberg, TJ, Engroff, SL. 2004. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62: 527-534
31. Friedlander, AH. 2002. The physiology, medical management and oral implications of menopause. J Am Dent Assoc 133: 73-81
32. Von Wowern, N. 2001. General and oral aspects of osteoporosis: A review. Clin Oral Investig 5: 71-82
33. Cutando, A, Gomez-Moreno, G, Arana, C, Acuna-Castroviejo, D, Reiter, RJ. 2007. Melatonin: Potential functions in the oral cavity. J Periodontolog 78: 1094-1102
34. Carrillo-Vico, A, Lardone, PJ, Naji, L et al. 2005. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: Regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res 39: 400-408
35. Guardia, J, Gomez-Moreno, G, Ferrera, MJ, Cutando, A. 2009. Evaluation of effects of topical melatonin on implant surface at 5 and 8 weeks in beagle dogs. Clin Implant Dent Relat Res. doi: 0.1111/j.1708-8208.2009.00211.x
36. Cutando, A, Gomez-Moreno, G, Arana, C et al. 2008. Melatonin stimulates osteointegration of dental implants. J Pineal Res 45: 174-179
37. Calvo-Guirado, JL, Gomez-Moreno, G, Barone, A et al. 2009. Melatonin plus porcine bone on discrete calcium deposit implant surface stimulates osteointegration in dental implants. J Pineal Res 47: 164-172
38. Takechi, M, Tatehara, S, Satomura, K, Fujisawa, K, Nagayama, M. 2008. Effect of FGF-2 and melatonin on implant bone healing: A histomorphometric study. J Mater Sci Mater Med 19: 2949-2952
39. Munoz, F, Lopez-Pena, M, Mino, N, Gomez-Moreno, G, Guardia, J, Cutando, A. 2009. Topical application of melatonin and growth hormone accelerates bone healing around dental implants in dogs. Clin Implant Dent Relat Res. doi: 10.1111/j.1708-8208.2009.00242.x
40. Radio, NM, Doctor, JS, Witt-Enderby, PA. 2006. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J Pineal Res 40: 332-342
41. Roth, JA, Kim, BG, Lin, WL, Cho, MI. 1999. Melatonin promotes osteoblast differentiation and bone formation. J Biol Chem 274: 22041-22047
42. Satomura, K, Tobiume, S, Tokuyama, R et al. 2007. Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo. J Pineal Res 42: 231-239
43. Nakade, O, Koyama, H, Ariji, H, Yajima, A, Kaku, T. 1999. Melatonin stimulates proliferation and type I collagen synthesis in human bone cells in vitro. J Pineal Res 27: 106-110
44. Suzuki, N, Hattori, A 2002. Melatonin suppresses osteoclastic and osteoblastic activities in the scales of goldfish. J Pineal Res 33: 253-258
45. Koyama, H, Nakade, O, Takada, Y, Kaku, T, Lau, KH. 2002. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res 17: 1219-1229
46. Sethi, S, Radio, NM, Kotlarczyk, MP et al. 2010. Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res. doi: 10.1111/j.1600-079X.2010.00784.x
47. Thomas, D, Kansara, M. 2006. Epigenetic modifications in osteogenic differentiation and transformation. J Cell Biochem 98: 757-769
48. Wada, T, Nakashima, T, Hiroshi, N, Penninger, JM. 2006. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12: 17-25
49. Boyce, BF, Xing, L. 2007. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 5: 98-104
50. Mckay, WF, Peckham, SM, Badura, JM. 2007. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int Orthop 31: 729-734
51. Chen, D, Zhao, M, Mundy, GR. 2004. Bone morphogenetic proteins. Growth Factors 22: 233-241
52. Derynck, R, Zhang, YE. 2003. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584
53. Miyazono, K, Maeda, S, Imamura, T. 2005. BMP receptor signaling: Transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 16: 251-263
54. Lee, MH, Kim, YJ, Kim, HJ et al. 2003. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 278: 34387-34394
55. Nakashima, K, Zhou, X, Kunkel, G et al. 2002. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108: 17-29
56. Huang, W, Yang, S, Shao, J, Li, YP 2007. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci 12: 3068-3092
57. Day, TF, Guo, X, Garrett-Beal, L, Yang, Y. 2005. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8: 739-750
58. Chau, JF, Leong, WF, Li, B. 2009. Signaling pathways governing osteoblast proliferation, differentiation and function. Histol Histopathol 24: 1593-1606
59. Guo, X, Wang, XF. 2009. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 19: 71-88
60. Rawadi, G, Ferrer, C, Spinella-Jaegle, S, Roman-Roman, S, Bouali, Y, Baron, R. 2001. 1-(5-Oxohexyl)-3,7-Dimethylxanthine, a phosphodiesterase inhibitor, activates MAPK cascades and promotes osteoblast differentiation by a mechanism independent of PKA activation (pentoxifylline promotes osteoblast differentiation). Endocrinology 142: 4673-4682
61. Suzuki, A, Palmer, G, Bonjour, JP, Caverzasio, J. 1999. Regulation of alkaline phosphatase activity by p38 MAP kinase in response to activation of Gi protein-coupled receptors by epinephrine in osteoblast-like cells. Endocrinology 140: 3177-3182
62. Matsushita, T, Chan, YY, Kawanami, A, Balmes, G, Landreth, GE, Murakami, S. 2009. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol Cell Biol 29: 5843-5857
63. Fraser, JH, Helfrich, MH, Wallace, HM, Ralston, SH. 1996. Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. Bone 19: 223-226
64. Sanchez-Rodriguez, MA, Ruiz-Ramos, M, Correa-Munoz, E, Mendoza-Nunez, VM. 2007. Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskelet Disord 8: 124
65. Woods, NF, Mitchell, ES. 2005. Symptoms during the perimenopause: Prevalence, severity, trajectory, and significance in women's lives. Am J Med 118 Suppl 12B: 14-24
66. Wade, A, Downie, S. 2008. Prolonged-release melatonin for the treatment of insomnia in patients over 55 years. Expert Opin Invest Drugs 17: 1567-1572
67. Guicheux, J, Lemonnier, J, Ghayor, C, Suzuki, A, Palmer, G, Caverzasio, J. 2003. Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 18: 2060-2068
68. Ge, C, Xiao, G, Jiang, D, Franceschi, RT. 2007. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J Cell Biol 176: 709-718
69. Ahmed, I, Gesty-Palmer, D, Drezner, MK, Luttrell, LM. 2003. Transactivation of the epidermal growth factor receptor mediates parathyroid hormone and prostaglandin F2 alpha-stimulated mitogen-activated protein kinase activation in cultured transgenic murine osteoblasts. Mol Endocrinol 17: 1607-1621